Larry Dobrow

Most Recent Articles by Larry Dobrow

Avanir marketing chief on selling first-in-class therapies

Avanir marketing chief on selling first-in-class therapies

Avanir's success with Nuedexta sparked the attention of several suitors. In 2014 the company reached a deal to be sold to Otsuka Pharmaceutical for around $3.5 billion

Leadership Exchange: Engaging the Millennial Doctor

Leadership Exchange: Engaging the Millennial Doctor

In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

What do physicians think about biosimilars?

What do physicians think about biosimilars?

A SERMO poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"

Post Pfizer, Allergan faces the future

Post Pfizer, Allergan faces the future

Mere days after the Pfizer deal collapsed, top Allergan executives had nary an air of regret about them.

More Articles by Larry Dobrow

OPINION

Email Newsletters